The worry usually arrives in a specific form. Words go missing mid-sentence, a familiar name will not come, concentration that used to be automatic now takes effort — and somewhere underneath is the thought that this is what the beginning of dementia looks like. It is a common fear, it is rarely said out loud, and there is now enough research to say something useful about it.

How Common the Experience Is

Not unusual, and not a minority experience. A 2026 research roadmap in Nature Reviews Neurology states that approximately two thirds of women experience cognitive concerns during the menopausal transition (Bove & Dobson, 2026).

That figure is worth sitting with, because the private version of this experience tends to assume it is happening to you alone. Two in three is closer to the ordinary course of the transition than to an exception.

What Is Actually Changing

The transition is characterised by hormonal fluctuation culminating in a decline in oestrogen, and oestrogen is not solely a reproductive hormone. A 2026 review describes its decline as affecting synaptic plasticity, neurotransmitter regulation, the blood–brain barrier, cerebral blood flow and metabolism — producing the cognitive symptoms usually described as brain fog.

That list is the reason the framing in the title matters. A change acting on cerebral blood flow and synaptic plasticity is a neurological event that happens to be triggered by a reproductive one, and describing it only in reproductive terms loses the part that explains the symptoms.

What "Cognitive Concerns" Actually Means Here

The phrase covers a narrower and more specific set of experiences than it sounds like. What women describe during the transition is typically word-finding difficulty, slowed recall of names and details, and concentration that has stopped being automatic — effortful rather than absent.

That profile matters for interpretation. Difficulty retrieving a word you clearly still possess is a different phenomenon from having lost it, and the distinction is part of why the 2026 review can describe these changes as differing in kind from progressive decline rather than differing only in degree.

It also explains why the experience is so frequently under-reported. Symptoms that are intermittent, that improve with rest, and that are invisible to everyone else are easy to attribute to being busy, tired or older — and easy to leave out of a medical appointment booked for something else.

The Answer to the Fear

The same review is direct about the distinction people are actually worried about: menopause-related cognitive changes are often transient, and they differ from the progressive decline seen in Alzheimer’s disease.

Two different words are doing work there. Transient means the trajectory is not one-directional. Differ means these are not early versions of the same process.

Neither word is a guarantee about any individual, and ‘often’ is not ‘always’. But the general shape of the evidence does not support reading midlife cognitive symptoms as the opening phase of a degenerative condition.

The Part the Roadmap Is Actually About

A roadmap is published when a field needs direction, and this one is unusually blunt about why. It states that menopause is under-recognised as a biological and sociocultural contributor to brain health, and that scientific understanding of the impact the menopausal transition has on the brain is minimal.

It names specific holes: insufficient data on the experience of women with established neurological conditions during perimenopause, on the mechanisms behind postmenopausal changes in disease course, and on how to manage neurological conditions in a sex-specific way.

The word sociocultural in that sentence is not decoration either. A transition that is under-discussed, that arrives during peak career and caregiving years, and that is frequently attributed to stress or ageing instead, produces a research literature shaped by what got reported and studied — which is part of why the roadmap treats the gap itself as the finding rather than an aside.

That is a strange thing to be true of a transition that every woman who lives long enough goes through. It is also the honest headline — not a discovery about menopause and the brain, but a documented account of how much is still not known.

What the Evidence Does Not Support

Four limits worth stating plainly.

Hormone therapy is not a dementia-prevention strategy. The 2026 review states that current evidence does not support using exogenous oestrogen solely for dementia prevention. Hormone therapy can help manage menopausal symptoms and should be personalised — which is a different clinical question from preventing a degenerative disease.

Timing appears to matter, and is not fully understood. The roadmap notes that earlier menopause is associated with greater risk of cognitive decline. That is an association drawn across populations; it does not establish a mechanism and it cannot be applied to an individual’s timing.

And the two-thirds figure is about reported concerns. It describes how many women experience and report cognitive difficulty during the transition, not how many show measurable change on testing. Those are related but not identical questions, and conflating them overstates what is known.

And a roadmap is not a result. It is a statement of where a field intends to go, written by researchers who think it has not gone there yet. Everything in it about mechanism should be read as the current best account awaiting the studies the roadmap is asking for, not as settled.

Why the Framing Change Is Useful

Because a symptom attributed to the wrong system gets managed by the wrong specialist, or dismissed entirely. Cognitive difficulty framed as a reproductive side effect invites waiting it out; framed as a neurological transition, it becomes something to describe accurately and track.

It also changes what counts as relevant. Sleep disruption, mood change and cognitive symptoms in this period are frequently treated as separate complaints when they may be closer to one system under a sustained change — which is why what happens to sleep matters well beyond tiredness.

And the broader point is the one that runs through most of this research: regulation is not fixed, and a transition is by definition something the system is moving through. That is the reasoning behind what the prevention evidence supports.